Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870944 · ClinicalTrials.gov registry record · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 20
- Study locations
NCT04870944: Recruiting Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by Children's Oncology Group.
NCT04870944 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 63 participants, roughly in line with the 63-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04870944, a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Echocardiography Test
- PROCEDURE Bone Marrow Aspirate
- DRUG FACT Complex-targeting Curaxin CBL0137
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Illinois
- Lurie Children's Hospital-Chicago - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Washington University School of Medicine - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
Alabama
- Children's Hospital of Alabama - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT04870944 shows while recruiting
NCT04870944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 63-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target.
The record links to 10 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04870944 names 20 study sites across 15 states, led by California, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT04870944 about?
NCT04870944 is a clinical study titled "CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma". This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block sig...
What is the current status of trial NCT04870944?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2022-01-28. Estimated completion is 2026-12-31.
What conditions does trial NCT04870944 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Refractory Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Lymphoma, Recurrent Diffuse Intrinsic Pontine Glioma.
What interventions are being tested in trial NCT04870944?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Echocardiography Test (PROCEDURE), Bone Marrow Aspirate (PROCEDURE), FACT Complex-targeting Curaxin CBL0137 (DRUG).
Who is sponsoring clinical trial NCT04870944?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04870944 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04870944's enrollment target sits among peer trials
63 11th of 59 higher than 49 of 59 other Refractory Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
- NCT05371613 · 63 participants · Phase 2
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI